科研之友
微信
新浪微博
Facebook
分享链接
摘要
The management of renal cell carcinoma (RCC) has evolved considerably following the introduction of targeted agents such as the receptor tyrosine kinase inhibitor sunitinib. Greater understanding of these agents is helping to define their optimal use in clinical practice.
- 出版日期2008
